|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL13RA2 |
Gene summary for IL13RA2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL13RA2 | Gene ID | 3598 |
| Gene name | interleukin 13 receptor subunit alpha 2 | |
| Gene Alias | CD213A2 | |
| Cytomap | Xq23 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q14627 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3598 | IL13RA2 | ATC09 | Human | Thyroid | ATC | 1.71e-46 | 2.54e+00 | 0.2871 |
| 3598 | IL13RA2 | ATC12 | Human | Thyroid | ATC | 4.82e-02 | 1.82e-01 | 0.34 |
| 3598 | IL13RA2 | ATC13 | Human | Thyroid | ATC | 1.84e-32 | 6.14e-01 | 0.34 |
| 3598 | IL13RA2 | ATC1 | Human | Thyroid | ATC | 1.64e-48 | 2.72e+00 | 0.2878 |
| 3598 | IL13RA2 | ATC4 | Human | Thyroid | ATC | 1.21e-03 | 2.36e-01 | 0.34 |
| 3598 | IL13RA2 | ATC5 | Human | Thyroid | ATC | 1.84e-32 | 6.69e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005165625 | Thyroid | ATC | establishment of organelle localization | 206/6293 | 390/18723 | 2.62e-15 | 1.84e-13 | 206 |
| GO:005105114 | Thyroid | ATC | negative regulation of transport | 183/6293 | 470/18723 | 8.12e-03 | 3.13e-02 | 183 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL13RA2 | SNV | Missense_Mutation | novel | c.115G>C | p.Glu39Gln | p.E39Q | Q14627 | protein_coding | tolerated(0.85) | benign(0.007) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| IL13RA2 | SNV | Missense_Mutation | c.985C>A | p.Gln329Lys | p.Q329K | Q14627 | protein_coding | tolerated(0.36) | benign(0.001) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| IL13RA2 | SNV | Missense_Mutation | c.202N>C | p.Glu68Gln | p.E68Q | Q14627 | protein_coding | tolerated(0.13) | benign(0.022) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| IL13RA2 | SNV | Missense_Mutation | c.881N>T | p.Thr294Ile | p.T294I | Q14627 | protein_coding | tolerated(0.56) | benign(0.003) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IL13RA2 | SNV | Missense_Mutation | c.967N>G | p.Ser323Gly | p.S323G | Q14627 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD | |
| IL13RA2 | SNV | Missense_Mutation | novel | c.1096N>A | p.Pro366Thr | p.P366T | Q14627 | protein_coding | tolerated(0.34) | benign(0.009) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| IL13RA2 | SNV | Missense_Mutation | c.590N>A | p.Cys197Tyr | p.C197Y | Q14627 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IL13RA2 | SNV | Missense_Mutation | rs375241228 | c.1027C>T | p.Arg343Cys | p.R343C | Q14627 | protein_coding | tolerated(0.17) | benign(0.03) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| IL13RA2 | SNV | Missense_Mutation | c.1032N>G | p.Phe344Leu | p.F344L | Q14627 | protein_coding | tolerated(0.29) | benign(0.02) | TCGA-A6-5660-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD | |
| IL13RA2 | SNV | Missense_Mutation | c.365N>G | p.Ser122Cys | p.S122C | Q14627 | protein_coding | deleterious(0.02) | benign(0.404) | TCGA-AA-3509-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3598 | IL13RA2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | Tralokinumab | TRALOKINUMAB | ||
| 3598 | IL13RA2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | AER001,AEROVANT | |||
| 3598 | IL13RA2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | CHEMBL2108583 | CINTREDEKIN BESUDOTOX | ||
| 3598 | IL13RA2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | ICT-107 | |||
| 3598 | IL13RA2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | CINTREDEKIN BESUDOTOX | |||
| 3598 | IL13RA2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | ABT-308 | CENDAKIMAB | ||
| 3598 | IL13RA2 | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | MB-101 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |